Trial Profile
Second phase II trial of MGCD 290 in patients with vulvovaginal candidiasis.
Status:
Planning
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 16 May 2012
Price :
$35
*
At a glance
- Drugs MGCD 290 (Primary)
- Indications Vulvovaginal candidiasis
- Focus Therapeutic Use
- 16 May 2012 New trial record